rofecoxib has been researched along with Inflammation in 45 studies
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herein, we report the effect of both inflammation and NSAIDs (rofecoxib, celecoxib, and meloxicam) on the physiologically active cytochrome P450 metabolites of arachidonic acid (ArA) in the rat with adjuvant arthritis." | 7.88 | Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid. ( Aghazadeh-Habashi, A; Asghar, W; Jamali, F, 2018) |
| "The effect of rofecoxib (Vioxx), a cyclooxygenase (COX)-2 inhibitor, on adipose tissue development was studied in a murine model of diet-induced obesity." | 7.74 | Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. ( Gallacher, DJ; Lijnen, HR; Lu, HR; Van Hoef, B, 2008) |
| "Despite the apparent correlation between [(11)C]rofecoxib uptake and COX-2 distribution in healthy rats, [(11)C]rofecoxib could not unambiguously detect COX-2 overexpression in two rat models of inflammation." | 7.74 | Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. ( de Vries, EF; Dierckx, RA; Doorduin, J; van Waarde, A, 2008) |
| "This study evaluates the action of celecoxib and rofecoxib, two selective cyclooxygenase-2 (COX-2) inhibitors in two acute models of inflammation, carrageenan (Cg)-induced rat pleurisy, and paw oedema formation." | 7.71 | Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. ( Calixto, JB; Pinheiro, RM, 2002) |
| "Both rofecoxib and ibuprofen treatment increased the gene expression of the pro-inflammatory mediators, IL6 and CCL2 (chemokine C-C motif ligand 2), following tissue injury compared to the placebo treatment." | 6.73 | Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. ( Dionne, RA; Hamza, M; Ramsay, ES; Wahl, SM; Wang, XM; Wu, TX, 2007) |
| " Herein, we report the effect of both inflammation and NSAIDs (rofecoxib, celecoxib, and meloxicam) on the physiologically active cytochrome P450 metabolites of arachidonic acid (ArA) in the rat with adjuvant arthritis." | 3.88 | Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid. ( Aghazadeh-Habashi, A; Asghar, W; Jamali, F, 2018) |
| " At this time, celecoxib is the only available COX-2-specific inhibitor for treatment of pain and inflammation." | 3.85 | COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages. ( Carsons, SE; De Leon, J; Gomolin, IH; Kasselman, LJ; Littlefield, MJ; Reiss, AB; Voloshyna, I, 2017) |
| "Substituted thiazoles with different structural features were synthesized and screened for their anti-inflammatory activity in acute carrageenin induced rat paw edema model and chronic formalin induced rat paw edema model." | 3.74 | 2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. ( Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S, 2008) |
| "The effect of rofecoxib (Vioxx), a cyclooxygenase (COX)-2 inhibitor, on adipose tissue development was studied in a murine model of diet-induced obesity." | 3.74 | Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. ( Gallacher, DJ; Lijnen, HR; Lu, HR; Van Hoef, B, 2008) |
| "In view of the well-established anti-inflammatory properties of latex of Calotropis procera (DL), the present study was carried out to evaluate the protective effect of its methanol extract (MeDL) against inflammation and oxidative stress in monoarthritis induced by Freund's complete adjuvant (FCA) in rats." | 3.74 | Calotropis procera latex extract affords protection against inflammation and oxidative stress in Freund's complete adjuvant-induced monoarthritis in rats. ( Kumar, VL; Roy, S, 2007) |
| "Despite the apparent correlation between [(11)C]rofecoxib uptake and COX-2 distribution in healthy rats, [(11)C]rofecoxib could not unambiguously detect COX-2 overexpression in two rat models of inflammation." | 3.74 | Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. ( de Vries, EF; Dierckx, RA; Doorduin, J; van Waarde, A, 2008) |
| "To examine the ability of rofecoxib prophylaxis to blunt the effect of monosodium urate (MSU) crystal inflammation induced in the rat subcutaneous air pouch." | 3.73 | Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch. ( Chen, LX; Clayburne, G; Nalbant, S; Schumacher, HR; Sieck, MS, 2005) |
| "Rofecoxib is a selective cyclooxygenase (COX)-2 inhibitor approved for the treatment of pain and inflammation in rheumatoid and osteoarthritis." | 3.72 | Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation. ( Geisslinger, G; Grösch, S; Niederberger, E; Schäfer, C; Seegel, M; Tegeder, I, 2003) |
| "The anti-inflammatory activity of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), was studied on the carrageenan-induced paw inflammation in the rat." | 3.72 | Studies on the anti-inflammatory effect of fluoxetine in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR, 2004) |
| "This study evaluates the action of celecoxib and rofecoxib, two selective cyclooxygenase-2 (COX-2) inhibitors in two acute models of inflammation, carrageenan (Cg)-induced rat pleurisy, and paw oedema formation." | 3.71 | Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. ( Calixto, JB; Pinheiro, RM, 2002) |
| "Both rofecoxib and ibuprofen treatment increased the gene expression of the pro-inflammatory mediators, IL6 and CCL2 (chemokine C-C motif ligand 2), following tissue injury compared to the placebo treatment." | 2.73 | Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. ( Dionne, RA; Hamza, M; Ramsay, ES; Wahl, SM; Wang, XM; Wu, TX, 2007) |
| " No significant difference between the three dosage groups was observed." | 2.71 | Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model. ( Anzenhofer, S; Chizh, B; Eichler, HG; Gustorff, B; Lehr, S; Schmetterer, L; Sycha, T, 2005) |
| " Moreover, some epidemiologic and pilot clinical studies have proven that long-term administration of anti-inflammatory drugs have a protective effect on the onset of AD." | 2.41 | Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs. ( Ferencik, M; Novak, M; Rovensky, J; Rybar, I, 2001) |
| "Acute inflammation was induced by sub-plantar injection of carrageenan (1%) in the rat hind paw." | 1.31 | Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR; El-Batran, S; El-Shenawy, SM, 2002) |
| "2." | 1.31 | Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. ( Bakhle, YS; Chaves, CT; Ferreira-Alves, DL; Francischi, JN; Lima, AS; Moura, AC; Rocha, OA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (82.22) | 29.6817 |
| 2010's | 7 (15.56) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Feixas, J | 1 |
| Jiménez, JM | 1 |
| Godessart, N | 1 |
| Puig, C | 1 |
| Soca, L | 1 |
| Crespo, MI | 1 |
| Almansa, C | 1 |
| Alfón, J | 1 |
| de Arriba, AF | 1 |
| Cavalcanti, FL | 1 |
| Escamilla, I | 1 |
| Gómez, LA | 1 |
| Miralles, A | 1 |
| Soliva, R | 1 |
| Bartrolí, J | 1 |
| Carceller, E | 1 |
| Merlos, M | 1 |
| García-Rafanell, J | 1 |
| Khanapure, SP | 2 |
| Garvey, DS | 2 |
| Young, DV | 2 |
| Ezawa, M | 1 |
| Earl, RA | 2 |
| Gaston, RD | 1 |
| Fang, X | 1 |
| Murty, M | 1 |
| Martino, A | 1 |
| Shumway, M | 1 |
| Trocha, M | 1 |
| Marek, P | 1 |
| Tam, SW | 1 |
| Janero, DR | 2 |
| Letts, LG | 2 |
| Augustyniak, ME | 1 |
| Martino, AM | 1 |
| Murty, MG | 1 |
| Schwalb, DJ | 1 |
| Shumway, MJ | 1 |
| Trocha, AM | 1 |
| Zemtseva, IS | 1 |
| Franklin, PX | 1 |
| Pillai, AD | 1 |
| Rathod, PD | 1 |
| Yerande, S | 1 |
| Nivsarkar, M | 1 |
| Padh, H | 1 |
| Vasu, KK | 1 |
| Sudarsanam, V | 1 |
| Swarbrick, ME | 1 |
| Beswick, PJ | 1 |
| Gleave, RJ | 1 |
| Green, RH | 1 |
| Bingham, S | 1 |
| Bountra, C | 1 |
| Carter, MC | 1 |
| Chambers, LJ | 1 |
| Chessell, IP | 1 |
| Clayton, NM | 1 |
| Collins, SD | 1 |
| Corfield, JA | 1 |
| Hartley, CD | 1 |
| Kleanthous, S | 1 |
| Lambeth, PF | 1 |
| Lucas, FS | 1 |
| Mathews, N | 1 |
| Naylor, A | 1 |
| Page, LW | 1 |
| Payne, JJ | 1 |
| Pegg, NA | 1 |
| Price, HS | 1 |
| Skidmore, J | 1 |
| Stevens, AJ | 1 |
| Stocker, R | 1 |
| Stratton, SC | 1 |
| Stuart, AJ | 1 |
| Wiseman, JO | 1 |
| Colucci, J | 1 |
| Boyd, M | 1 |
| Berthelette, C | 1 |
| Chiasson, JF | 1 |
| Wang, Z | 1 |
| Ducharme, Y | 1 |
| Friesen, R | 1 |
| Wrona, M | 1 |
| Levesque, JF | 1 |
| Denis, D | 1 |
| Mathieu, MC | 1 |
| Stocco, R | 1 |
| Therien, AG | 1 |
| Clarke, P | 1 |
| Rowland, S | 1 |
| Xu, D | 1 |
| Han, Y | 1 |
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Werner, S | 1 |
| Mesch, S | 1 |
| Hillig, RC | 1 |
| Ter Laak, A | 1 |
| Klint, J | 1 |
| Neagoe, I | 1 |
| Laux-Biehlmann, A | 1 |
| Dahllöf, H | 1 |
| Bräuer, N | 1 |
| Puetter, V | 1 |
| Nubbemeyer, R | 1 |
| Schulz, S | 1 |
| Bairlein, M | 1 |
| Zollner, TM | 1 |
| Steinmeyer, A | 1 |
| Araújo, PHF | 1 |
| Ramos, RS | 1 |
| da Cruz, JN | 1 |
| Silva, SG | 1 |
| Ferreira, EFB | 1 |
| de Lima, LR | 1 |
| Macêdo, WJC | 1 |
| Espejo-Román, JM | 1 |
| Campos, JM | 1 |
| Santos, CBR | 1 |
| Kaur, G | 1 |
| Silakari, O | 1 |
| Aghazadeh-Habashi, A | 1 |
| Asghar, W | 1 |
| Jamali, F | 1 |
| Voloshyna, I | 1 |
| Kasselman, LJ | 1 |
| Carsons, SE | 1 |
| Littlefield, MJ | 1 |
| Gomolin, IH | 1 |
| De Leon, J | 1 |
| Reiss, AB | 1 |
| Lijnen, HR | 1 |
| Van Hoef, B | 1 |
| Lu, HR | 1 |
| Gallacher, DJ | 1 |
| Kumar, VL | 2 |
| Roy, S | 2 |
| Amaya, F | 1 |
| Samad, TA | 1 |
| Barrett, L | 1 |
| Broom, DC | 1 |
| Woolf, CJ | 1 |
| Alizzi, AM | 1 |
| Summers, P | 1 |
| Boon, VH | 1 |
| Tantiongco, JP | 1 |
| Thompson, T | 1 |
| Leslie, BJ | 1 |
| Williams, D | 1 |
| Steele, M | 1 |
| Bidstrup, BP | 1 |
| Diqer, AM | 1 |
| El-Shenawy, SM | 1 |
| Abdel-Salam, OM | 2 |
| Baiuomy, AR | 2 |
| El-Batran, S | 1 |
| Arbid, MS | 2 |
| Francischi, JN | 1 |
| Chaves, CT | 1 |
| Moura, AC | 1 |
| Lima, AS | 1 |
| Rocha, OA | 1 |
| Ferreira-Alves, DL | 1 |
| Bakhle, YS | 1 |
| Pinheiro, RM | 1 |
| Calixto, JB | 1 |
| Niederberger, E | 1 |
| Tegeder, I | 1 |
| Schäfer, C | 1 |
| Seegel, M | 1 |
| Grösch, S | 1 |
| Geisslinger, G | 1 |
| Klivenyi, P | 1 |
| Gardian, G | 1 |
| Calingasan, NY | 1 |
| Yang, L | 1 |
| Beal, MF | 1 |
| Patrignani, P | 1 |
| Jayr, C | 1 |
| Bogaty, P | 1 |
| Brophy, JM | 1 |
| Noel, M | 1 |
| Boyer, L | 1 |
| Simard, S | 1 |
| Bertrand, F | 1 |
| Dagenais, GR | 1 |
| Rahusen, FT | 1 |
| Weinhold, PS | 1 |
| Almekinders, LC | 1 |
| Sycha, T | 1 |
| Anzenhofer, S | 1 |
| Lehr, S | 1 |
| Schmetterer, L | 1 |
| Chizh, B | 1 |
| Eichler, HG | 1 |
| Gustorff, B | 1 |
| Lacomblez, L | 1 |
| Nalbant, S | 1 |
| Chen, LX | 1 |
| Sieck, MS | 1 |
| Clayburne, G | 1 |
| Schumacher, HR | 1 |
| Aydin, MV | 1 |
| Sen, O | 1 |
| Kayaselcuk, F | 1 |
| Bolat, F | 1 |
| Tufan, K | 1 |
| Caner, H | 1 |
| Altinors, N | 1 |
| Blake, DR | 1 |
| Shenker, N | 1 |
| Cohen, H | 1 |
| Stevens, CR | 1 |
| Rotondo, S | 1 |
| Dell'Elba, G | 1 |
| Manarini, S | 1 |
| Cerletti, C | 1 |
| Evangelista, V | 1 |
| Wang, XM | 1 |
| Wu, TX | 1 |
| Hamza, M | 1 |
| Ramsay, ES | 1 |
| Wahl, SM | 1 |
| Dionne, RA | 1 |
| Murphy, JO | 1 |
| Ravi, N | 1 |
| Byrne, PJ | 1 |
| McDonald, GS | 1 |
| Reynolds, JV | 1 |
| Underwood, A | 1 |
| Feng, Y | 1 |
| Ju, H | 1 |
| Yang, B | 1 |
| An, H | 1 |
| Murase, A | 2 |
| Okumura, T | 2 |
| Sakakibara, A | 1 |
| Tonai-Kachi, H | 1 |
| Nakao, K | 1 |
| Takada, J | 1 |
| de Vries, EF | 1 |
| Doorduin, J | 1 |
| Dierckx, RA | 1 |
| van Waarde, A | 1 |
| Murata, Y | 1 |
| Taniguchi, K | 1 |
| Nii, A | 1 |
| Ferencik, M | 1 |
| Novak, M | 1 |
| Rovensky, J | 1 |
| Rybar, I | 1 |
| Mejza, F | 1 |
| Nizankowska, E | 1 |
| Kessenich, CR | 1 |
| Martínez, RV | 1 |
| Reval, M | 1 |
| Campos, MD | 1 |
| Terrón, JA | 1 |
| Domínguez, R | 1 |
| López-Muñoz, FJ | 1 |
5 reviews available for rofecoxib and Inflammation
| Article | Year |
|---|---|
Multiple target-centric strategy to tame inflammation.
Topics: Cyclooxygenase Inhibitors; Humans; Inflammation; Lactones; Lipoxygenase; Lipoxygenase Inhibitors; Mo | 2017 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cycl | 2004 |
Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxygenas | 2001 |
[Selective cyclooxygenase 2 inhibitors (COX-2)].
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
Cyclo-oxygenase 2 inhibitors: an important new drug classification.
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Chr | 2001 |
5 trials available for rofecoxib and Inflammation
| Article | Year |
|---|---|
Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Biomarkers; Brachial Artery; C-Rea | 2004 |
Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model.
Topics: Adult; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dose-Respons | 2005 |
Analysis and prevalence of inflammatory cells in subtypes of lumbar disc herniations under cyclooxygenase-2 inhibitor therapy.
Topics: Adult; Aged; Antigens, CD; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; B-Lymphocytes; | 2005 |
Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Cyclooxygenase 2 Inhibitors; Cytokines; | 2007 |
Effects of a selective cyclooxygenase-2 inhibitor on postoperative inflammatory reaction and pain after total knee replacement.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Arthritis; Arthroplasty, Replacement, Knee; Chemotax | 2008 |
35 other studies available for rofecoxib and Inflammation
| Article | Year |
|---|---|
Naphthalene derivatives: A new series of selective cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2001 |
Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites | 2003 |
Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.
Topics: Acute Disease; Administration, Oral; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox | 2003 |
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
Topics: Administration, Oral; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxyg | 2005 |
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhib | 2008 |
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Di | 2009 |
Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.
Topics: Animals; Arthritis; Benzoates; Cells, Cultured; Dogs; Drug Discovery; Drug Stability; Hepatocytes; H | 2010 |
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Discovery and Characterization of the Potent and Selective P2X4 Inhibitor
Topics: Acetamides; Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochr | 2019 |
Identification of Potential COX-2 Inhibitors for the Treatment of Inflammatory Diseases Using Molecular Modeling Approaches.
Topics: Animals; Binding Sites; Caco-2 Cells; Celecoxib; Cyclooxygenase 2 Inhibitors; Dogs; Drug Evaluation, | 2020 |
Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arthritis, Experimental; Celecox | 2018 |
COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biological Transport; Celecoxib; Cell Adhe | 2017 |
Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity.
Topics: Adipose Tissue; Animals; Blood Glucose; Cyclooxygenase 2 Inhibitors; Dietary Fats; Disease Models, A | 2008 |
Protective effect of latex of Calotropis procera in Freund's Complete Adjuvant induced monoarthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Calotropis; Freund's Adjuvant; Inflammat | 2009 |
Periganglionic inflammation elicits a distally radiating pain hypersensitivity by promoting COX-2 induction in the dorsal root ganglion.
Topics: Analysis of Variance; Animals; Autonomic Fibers, Preganglionic; Behavior, Animal; Biophysics; Cycloo | 2009 |
Reduction of post-surgical pericardial adhesions using a pig model.
Topics: Animals; Biological Availability; Biomarkers; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Mod | 2012 |
Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat.
Topics: Administration, Topical; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib | 2002 |
Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; | 2002 |
Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Disease Models, Animal; Inflammat | 2003 |
Studies on the anti-inflammatory effect of fluoxetine in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Carrageenan; Celecoxib; Cyc | 2004 |
Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Topics: Animals; Creatine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease | 2003 |
[Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygena | 2003 |
Nonsteroidal anti-inflammatory drugs and acetaminophen in the treatment of an acute muscle injury.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Stero | 2004 |
[Inflammation, nonsteroidal anti-inflammatory drugs and Alzheimer disease].
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxy | 2004 |
Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch.
Topics: Animals; Arthritis, Gouty; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Inflammation; | 2005 |
What if Derek Willoughby were right? Cyclo-oxygenase is an anti-inflammatory enzyme.
Topics: Cartoons as Topic; Cyclooxygenase 2 Inhibitors; History, 20th Century; History, 21st Century; Humans | 2005 |
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Elect | 2006 |
Calotropis procera latex extract affords protection against inflammation and oxidative stress in Freund's complete adjuvant-induced monoarthritis in rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Calotropis; Catalase; Dinoprostone; Fema | 2007 |
Neither antioxidants nor COX-2 inhibition protect against esophageal inflammation in an experimental model of severe reflux.
Topics: Animals; Antioxidants; Ascorbic Acid; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; | 2007 |
Life after Vioxx.
Topics: Arthritis; Cyclooxygenase 2 Inhibitors; Dietary Supplements; Drug and Narcotic Control; Humans; Infl | 2005 |
Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents; Benzamides; Benzoates; Cell Lin | 2008 |
Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation.
Topics: Animals; Brain; Carbon Radioisotopes; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, | 2008 |
Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone Resorption; Dinoprostone; Dose-Resp | 2008 |
Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain.
Topics: Animals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; Inflammation; Lactones | 2002 |